Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
Aug 27, 2024
Read MoreZai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
Aug 06, 2024
Read MoreZai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Jul 16, 2024
Read MoreZai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
Jul 15, 2024
Read MoreZai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Jul 10, 2024
Read MoreZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
Jun 11, 2024
Read MoreMETIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
Jun 03, 2024
Read More